# US 5,703,213 A · Monoclonal antibodies which recognize an adenocarcinoma cell antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,703,213 A
- Document ID: US5703213A
- Status: Granted
- Kind: A
- Application number: 08/193,673
- Filed: 1994-02-07
- Granted: 1997-12-30
- Earliest claimed: 1987-12-09
- Assignees: The General Hospital Corporation
- Inventors: Jack R. Wands; Hiroshi Takahashi
- Web page: https://patentgrep.com/patent/US5703213A

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 51/1048: {the tumor cell determinant being a carcino embryonic antigen}
- A61K 51/1093: {conjugates with carriers being antibodies}
- C07K 16/30: from tumour cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2123/00: Preparations for testing in vivo
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to antibodies, and fragments thereof, which specifically bind the AF-20 and the XF-8 epitopes of adenocarcinoma cell antigen(s).

## Claims

### Claim 1

A monoclonal antibody, or F(ab) or F(ab).sub.2 fragment thereof, which specifically binds to an adenocarcinoma cell antigen AF-20, and which has the epitope binding specificity of an antibody produced by hybridoma cell line ATCC designation HB 9687.

### Claim 2

A monoclonal antibody, or F(ab) or F(ab).sub.2 fragment thereof, which specifically binds to an adenocarcinoma cell antigen XF-8, and which has the epitope binding specificity of an antibody produced by hybridoma cell line ATCC designation HB 9686.

### Claim 3 (depends on 1)

The monoclonal antibody (MAb) of claim 1, wherein said MAb is a murine MAb.

### Claim 4 (depends on 2)

The monoclonal antibody (MAb) of claim 2, wherein said MAb is a murine MAb.

### Claim 5 (depends on 1)

The monoclonal antibody according to claim 1, which is produced by hybridoma cell line ATCC designation HB 9687.

### Claim 6 (depends on 2)

The monoclonal antibody according to claim 2, which is produced by hybridoma cell line ATCC designation HB 9686.

### Claim 7 (depends on 1)

A hybridoma cell line which produces the monoclonal antibody of claim 1.

### Claim 8 (depends on 2)

A hybridoma cell line which produces the monoclonal antibody of claim 2.

### Claim 9 (depends on 5)

A hybridoma cell line (ATCC designation HB 9687) which produces the monoclonal antibody of claim 5.

### Claim 10 (depends on 6)

A hybridoma cell line (ATCC designation HB 9686) which produces the monoclonal antibody of claim 6.